 |
市场调查报告书
商品编码
1935137
神经内分泌癌症治疗市场按药物类别、适应症类型、最终用户、给药途径、通路和地区划分Neuroendocrine Carcinoma Treatment Market, By Drug Class, By Indication Type, By End User, By Route of Administration, By Distribution Channel, By Geography |
||||||
预计到 2026 年，神经内分泌癌症治疗市场规模将达到 23.5 亿美元，到 2033 年将达到 40.8 亿美元，2026 年至 2033 年的复合年增长率为 8.2%。
| 报告内容 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2025 | 2026年市场规模： | 23.5亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2026年至2033年 |
| 预测期（2026-2033年）复合年增长率： | 8.20% | 2033 年的预测值： | 40.8亿美元 |
全球神经内分泌肿瘤治疗市场是肿瘤治疗领域的重要组成部分，旨在满足神经内分泌肿瘤（NETs）和神经内分泌癌（NECs）患者复杂的临床需求。这些罕见但日益受到重视的恶性肿瘤起源于分布于包括胃肠道、胰臟、肺臟和其他解剖部位在内的各种器官系统的神经内分泌细胞。神经内分泌癌的特征是异质性、分化程度不一以及临床表现多样，因此需要结合手术、全身性治疗和分子标靶治疗的综合治疗方法。
该市场涵盖了广泛的治疗方法，包括生长抑制素类似物、标靶治疗药物、化疗方案、胜肽受体放射性核素治疗（PRRT）以及新兴的免疫疗法。随着诊断技术的进步、对肿瘤生物学认识的加深以及医疗专业人员意识的提高，神经内分泌肿瘤的识别和治疗取得了显着进展。不断上升的发病率和创新治疗策略带来的生存率提升，为市场提供了巨大的成长机会。这个专业治疗市场持续吸引製药公司的大量投资，推动着针对特定肿瘤特征和患者情况的新型治疗模式和个人化医疗方法的发展。
市场动态
全球神经内分泌肿瘤治疗市场受多种强劲的市场驱动因素推动，其中包括由于诊断技术的进步和医疗专业人员临床意识的提高，全球神经内分泌肿瘤的发生率不断上升。先进的影像技术、分子诊断和生物标记识别显着提高了早期发现这些肿瘤的能力，从而扩大了需要治疗性介入的患者群体。製药公司不断增加的研发投入正在加速创新治疗方法的推出，例如标靶治疗、免疫疗法和精准医疗方法，与传统化疗方案相比，这些疗法具有更高的疗效和更低的副作用。
然而，该市场也面临许多限制因素，主要源自于神经内分泌肿瘤的罕见性，这限制了符合临床试验条件的患者数量，也使得新型治疗方法的监管核准面临挑战。高昂的治疗费用，尤其是新型标靶治疗和胜肽受体放射性核种疗法（PRRT）的费用，可能给医疗系统和患者带来沉重的经济负担，从而限制了市场准入。
此外，神经内分泌肿瘤的异质性使得治疗标准化变得复杂，而基层医疗医师对该疾病认识不足也可能导致诊断延迟和治疗效果不佳。儘管面临这些挑战，不断扩充的药物研发管线、联合治疗的普及以及基于肿瘤遗传学和患者个体因素的个人化治疗策略的日益重视，都带来了巨大的机会。开发中国家发病率的上升，加上医疗基础设施的改善和医疗成本的增加，为致力于满足神经内分泌肿瘤治疗领域未满足需求的製药公司创造了巨大的市场拓展机会。
本次调查的主要特点
- 本报告对全球神经内分泌癌症治疗市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）的市场规模（十亿美元）和復合年增长率（%）。
- 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 该研究根据以下参数对全球神经内分泌癌症治疗市场的主要参与者进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告的研究结果将使负责人和企业经营团队能够就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
- 这份全球神经内分泌癌症治疗市场报告的目标受众包括该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 相关人员可以透过各种策略矩阵更轻鬆地分析全球神经内分泌癌症治疗市场，从而做出决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
第三章 市场动态、监管与趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 重大进展
- 法规环境
- 产品上市及核准
- PEST分析
- 波特分析
- 併购趋势
- 产业趋势
4. 2021-2033年全球神经内分泌癌症治疗市场（依药物类别划分）
- 生长抑制素类似物
- 化疗药物
- 标靶治疗药物
- 免疫调节药物
- 胜肽受体放射性核种治疗（PRRT）
- 荷尔蒙
5. 2021-2033年全球神经内分泌肿瘤治疗市场（依适应症类型划分）
- 胃肠胰神经内分泌肿瘤（GEP-NETs）
- 肺神经内分泌肿瘤
- 甲状腺神经内分泌肿瘤
- 其他（例如，肾上腺神经内分泌肿瘤）
6. 2021-2033年全球神经内分泌肿瘤治疗市场（依最终使用者划分）
- 医院
- 癌症治疗中心
- 门诊手术中心
- 居家医疗
- 研究所
7. 2021-2033年全球神经内分泌肿瘤治疗市场（依给药途径划分）
- 口服
- 肠外
8. 2021-2033年全球神经内分泌癌症治疗市场（依通路划分）
- 医院药房
- 零售药房
- 网路药房
9. 2021-2033年全球神经内分泌肿瘤治疗市场（依地区划分）
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十章 竞争格局
- Novartis AG
- Ipsen Pharma
- Pfizer Inc
- BristolMyers Squibb
- Eli Lilly and Company
- Merck &Co
- Amgen
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Hutchison China MediTech
- Exelixis Inc
- Chiasma Inc
- Advanced Accelerator Applications（Novartis Radioligand）
- Progenics Pharmaceuticals
- AbbVie Inc
第十一章 分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map
第十二章 参考文献与调查方法
- 参考
- 调查方法
- 关于本公司
Neuroendocrine Carcinoma Treatment Market is estimated to be valued at USD 2.35 Bn in 2026 and is expected to reach USD 4.08 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.35 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 4.08 Bn |
The global neuroendocrine carcinoma treatment market represents a critical segment within the oncology therapeutics landscape, addressing the complex clinical needs of patients diagnosed with neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These rare but increasingly recognized malignancies arise from neuroendocrine cells distributed throughout various organ systems, including the gastrointestinal tract, pancreas, lungs, and other anatomical sites. Neuroendocrine carcinomas are characterized by their heterogeneous nature, varying degrees of differentiation, and diverse clinical presentations, necessitating sophisticated treatment approaches that combine surgical interventions, systemic therapies, and targeted molecular treatments.
The market encompasses a comprehensive range of therapeutic modalities including somatostatin analogs, targeted therapy agents, chemotherapy regimens, peptide receptor radionuclide therapy (PRRT), and emerging immunotherapeutic approaches. With advancing diagnostic capabilities, improved understanding of tumor biology, and growing awareness among healthcare professionals, the identification and treatment of neuroendocrine carcinomas have significantly evolved. The increasing incidence rates, coupled with enhanced survival outcomes through innovative treatment strategies, drives substantial market growth opportunities. This specialized therapeutic market continues to attract significant pharmaceutical investment, fostering the development of novel treatment paradigms and personalized medicine approaches tailored to specific tumor characteristics and patient profiles.
Market Dynamic
The global neuroendocrine carcinoma treatment market is propelled by several robust drivers, including the rising incidence of neuroendocrine tumors worldwide, attributed to improved diagnostic techniques and increased clinical awareness among healthcare professionals. Advanced imaging technologies, molecular diagnostics, and biomarker identification have significantly enhanced early detection capabilities, leading to expanded patient populations requiring therapeutic intervention. The growing investment in research and development by pharmaceutical companies has accelerated the introduction of innovative treatment modalities, including targeted therapies, immunotherapies, and precision medicine approaches that offer improved efficacy and reduced adverse effects compared to conventional chemotherapy regimens.
However, the market faces considerable restraints, primarily stemming from the rare nature of neuroendocrine carcinomas, which limits patient populations for clinical trials and creates challenges in achieving regulatory approvals for new treatments. High treatment costs, particularly for novel targeted therapies and peptide receptor radionuclide therapy, create significant financial burdens for healthcare systems and patients, potentially limiting market accessibility.
Additionally, the heterogeneous nature of neuroendocrine tumors complicates treatment standardization, while limited awareness among primary care physicians may result in delayed diagnoses and suboptimal treatment outcomes. Despite these challenges, substantial opportunities emerge from the expanding pipeline of investigational drugs, increasing adoption of combination therapy approaches, and growing focus on personalized treatment strategies based on tumor genetics and patient-specific factors. The rising prevalence in developing economies, coupled with improving healthcare infrastructure and increasing healthcare expenditure, presents significant market expansion opportunities for pharmaceutical companies seeking to address unmet medical needs in neuroendocrine carcinoma treatment.
Key Features of the Study
- This report provides in-depth analysis of the global neuroendocrine carcinoma treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neuroendocrine carcinoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Ipsen Pharma, Pfizer Inc, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co, Amgen, Boehringer Ingelheim, Teva Pharmaceutical Industries, Hutchison China MediTech, Exelixis Inc, Chiasma Inc, Advanced Accelerator Applications (Novartis Radioligand), Progenics Pharmaceuticals, and AbbVie Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neuroendocrine carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine carcinoma treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Somatostatin Analogs
- Chemotherapeutic Agents
- Targeted Therapy Drugs
- Immunomodulatory Drugs
- Peptide Receptor Radionuclide Therapy (PRRT)
- Hormonal Agents
- Indication Type Insights (Revenue, USD Bn, 2021 - 2033)
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Pulmonary Neuroendocrine Tumors
- Thyroid Neuroendocrine Tumors
- Others (e.g. Adrenal Gland Neuroendocrine Tumors)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Cancer Treatment Centers
- Ambulatory Surgery Centers
- Home Care
- Research Institutes
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Ipsen Pharma
- Pfizer Inc
- Bristol Myers Squibb
- Eli Lilly and Company
- Merck & Co
- Amgen
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Hutchison China MediTech
- Exelixis Inc
- Chiasma Inc
- Advanced Accelerator Applications (Novartis Radioligand)
- Progenics Pharmaceuticals
- AbbVie Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Neuroendocrine Carcinoma Treatment Market, By Drug Class
- Global Neuroendocrine Carcinoma Treatment Market, By Indication Type
- Global Neuroendocrine Carcinoma Treatment Market, By End User
- Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration
- Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel
- Global Neuroendocrine Carcinoma Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Neuroendocrine Carcinoma Treatment Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Somatostatin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Chemotherapeutic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunomodulatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Peptide Receptor Radionuclide Therapy (PRRT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hormonal Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Neuroendocrine Carcinoma Treatment Market, By Indication Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pulmonary Neuroendocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Thyroid Neuroendocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (e.g. Adrenal Gland Neuroendocrine Tumors)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Neuroendocrine Carcinoma Treatment Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ambulatory Surgery Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Home Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Neuroendocrine Carcinoma Treatment Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BristolMyers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hutchison China MediTech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Exelixis Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chiasma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Advanced Accelerator Applications (Novartis Radioligand)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Progenics Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
神经内分泌肿瘤治疗市场规模、份额和成长分析（按肿瘤类型、治疗产品、部位、最终用途和地区划分）—产业预测（2026-2033 年）
神经内分泌肿瘤治疗市场规模、份额、趋势分析报告：按类型、产品、地点、最终用途、地区和细分市场进行预测，2025 年至 2030 年
神经内分泌肿瘤治疗市场，按治疗类型、药物类别、肿瘤类型、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测全球神经内分泌肿瘤 (NET) 市场（2024 年版）：按治疗、给药途径、适应症、最终用户和区域、市场考虑因素和预测进行分析（2020-2030 年）